{
    "clinical_study": {
        "@rank": "6620", 
        "arm_group": [
            {
                "arm_group_label": "Ampicillin / sulbactam", 
                "arm_group_type": "Experimental", 
                "description": "Patients are randomized to the ampicillin / sulbactam arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions."
            }, 
            {
                "arm_group_label": "Amoxicillin / clavulanic acid", 
                "arm_group_type": "Experimental", 
                "description": "Patients are randomized to the amoxicillin / clavulanic acid arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions."
            }
        ], 
        "brief_summary": {
            "textblock": "The study will be conducted to investigate the pharmacokinetics of ampicillin / sulbactam\n      and amoxicillin/clavulanic acid during intermittent haemodialysis."
        }, 
        "brief_title": "Concentration of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients", 
        "condition": "Infection During Hemodialysis", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >18 years\n\n          -  Suspected or proven bacterial infection requiring parenteral antibiotic therapy.\n\n          -  Renal replacement therapy (HD)\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to ampicillin / sulbactam, amoxicillin / clavulanic acid or\n             other beta-lactames, or severe hypersensitivity (anaphylactic reaction) to\n             beta-lactam antibacterial agents.\n\n          -  An expected survival of less than two days.\n\n          -  Known pregnancy\n\n          -  Co-administration of one of the following drugs: probenecid which cannot be\n             discontinued for the duration of the study\n\n          -  Ampicillin / sulbactam respectively amoxicillin / clavulanic acid as monotherapy for\n             resistant species or fungal infections.\n\n          -  Other reasons opposing the study participation on the discretion of the\n             investigators."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02007603", 
            "org_study_id": "AMPISUL/AMOXICLAV-HD_V1.4"
        }, 
        "intervention": [
            {
                "arm_group_label": "Amoxicillin / clavulanic acid", 
                "description": "Patients receive amoxicillin / clavulanic acid due to clinical necessity", 
                "intervention_name": "Administration of Amoxicillin / clavulanic acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ampicillin / sulbactam", 
                "description": "Patients receive ampicillin / sulbactam due to clinical necessity", 
                "intervention_name": "Ampicillin / sulbactam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Ampicillin / sulbactam", 
                    "Amoxicillin / clavulanic acid"
                ], 
                "description": "Blood will be sampled at multiple timepoints during multiple hemodialysis sessions", 
                "intervention_name": "Blooddraws for pharmacokinetic profiling", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amoxicillin", 
                "Ampicillin", 
                "Clavulanic Acids", 
                "Clavulanic Acid", 
                "Sulbactam", 
                "Sultamicillin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "chronic hemodialysis", 
            "ampicillin", 
            "sulbactam", 
            "amoxicillin", 
            "clavulanic acid", 
            "pharmacokinetics"
        ], 
        "lastchanged_date": "December 17, 2013", 
        "location": {
            "contact": {
                "email": "florian.thalhammer@meduniwien.ac.at", 
                "last_name": "Florian Thalhammer, Prof. MD", 
                "phone": "0043140400", 
                "phone_ext": "4440"
            }, 
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "1090"
                }, 
                "name": "Medical University of Vienna"
            }, 
            "investigator": {
                "last_name": "Florian Thalhammer, Prof. MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multiple-dose Pharmacokinetics of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid During Haemodialysis in Longterm Haemodialysis Patients", 
        "overall_contact": {
            "email": "florian.thalhammer@meduniwien.ac.at", 
            "last_name": "Florian Thalhammer, Prof. MD", 
            "phone": "0043140400", 
            "phone_ext": "4440"
        }, 
        "overall_official": {
            "affiliation": "Medical University of Vienna", 
            "last_name": "Florian Thalhammer, Prof. MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Federal Office for Safety in Health Care", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinetic samples are drawn on multiple timepoints from each patient during his participation.", 
            "measure": "Influence of hemodialysis on the area under concentration curve of ampicillin/sulbactam and amoxicillin / clavulanic acid plasma concentration levels.", 
            "safety_issue": "No", 
            "time_frame": "day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02007603"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Vienna", 
            "investigator_full_name": "Florian Thalhammer", 
            "investigator_title": "a.o.Univ.-Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Medical University of Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Vienna", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}